碳酸氢钠治疗慢性肾脏病合并代谢性酸中毒的临床结局:一项Meta分析
结果显示碳酸氢钠可显著改善eGFR、降低住院率、增加中臂肌围,但收缩压升高风险较高,全因死亡率无显著差异。
要点
- 碳酸氢钠补充可显著改善CKD合并代谢性酸中毒患者的eGFR。
- 碳酸氢钠治疗与住院率降低相关,并增加中臂肌围。
- 碳酸氢钠治疗与收缩压升高风险较高相关,全因死亡率无显著差异。
核心结论
- 在CKD合并代谢性酸中毒患者中,碳酸氢钠补充可能有助于防止肾功能恶化和增加肌肉量,但可能与血压升高相关。
主要发现
- 碳酸氢钠组eGFR显著改善(SMD 0.33,95%CI 0.03至0.63,P=0.03)。
- 碳酸氢钠组住院率更低(OR 0.37,95%CI 0.25至0.55,P<0.001)。
- 碳酸氢钠组中臂肌围更高(SMD 0.23,95%CI 0.08至0.38,P=0.003,I2<0.001)。
- 碳酸氢钠组收缩压升高风险更高(SMD 0.10,95%CI 0.01至0.20,P=0.03)。
- 全因死亡率无显著差异。
临床怎么用
- 对CKD合并代谢性酸中毒患者,碳酸氢钠补充可能延缓肾功能下降并改善肌肉量,但需监测血压。
局限性
- 缺乏双盲设计导致偏倚风险。
- 各研究对照组定义不一致。
- 需进一步研究验证上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Sodium bicarbonate for patients with CKD and metabolic acidosis leads to a significant improvement in kidney function. Treatment with sodium bicarbonate increases in mid-arm muscle circumference, indicating a positive effect on enhancing muscle mass. Sodium bicarbonate supplementation is associated with a higher risk of elevated systolic BP, marking a potential side effect. BACKGROUND: In patients with CKD, impaired kidney acid excretion leads to the onset of metabolic acidosis (MA). However, the evidence is not yet conclusive regarding the effects of sodium bicarbonate in treating CKD with MA. METHODS: Databases with PubMed, Embase, and the Cochrane Library were used to search for randomized controlled trials (RCTs) from the inception until November 11, 2023, to identify RCTs investigating the effect of sodium bicarbonate in participants with CKD and MA. The primary outcome was the change in eGFR. Secondary outcomes included hospitalization rates, change in systolic BP, all-cause mortality, and mid-arm muscle circumference. A random-effects model was applied for analysis, and subgroup, sensitivity analyses were also performed. RESULTS: Fourteen RCTs comprising 2037 patients demonstrated that sodium bicarbonate supplementation significantly improved eGFR (standardized mean difference [SMD], 0.33; 95% confidence interval [CI], 0.03 to 0.63; P = 0.03). The group receiving sodium bicarbonate had a lower hospitalization rate (odds ratio, 0.37; 95% CI, 0.25 to 0.55; P < 0.001). Higher mid-arm muscle circumference was observed with sodium bicarbonate treatment compared with those without (SMD, 0.23; 95% CI, 0.08 to 0.38; P = 0.003, I2<0.001). However, higher risk of elevated systolic BP was found with sodium bicarbonate treatment (SMD, 0.10; 95% CI, 0.01 to 0.20; P = 0.03). No significant difference in all-cause mortality was noted. CONCLUSIONS: In patients with CKD and MA, sodium bicarbonate supplementation may provide potential benefits in preventing the deterioration of kidney function and increasing muscle mass. However, treatment may be associated with higher BP. Owing to the risk of bias stemming from the absence of double-blinded designs and inconsistencies in control group definitions across the studies, further research is crucial to verify these findings.
引用
- Yang TY, Lin HM, Wang HY, et al. Sodium Bicarbonate Treatment and Clinical Outcomes in Chronic Kidney Disease with Metabolic Acidosis: A Meta-Analysis. Clin J Am Soc Nephrol. 2024. PMID: 38980732. doi:10.2215/CJN.0000000000000487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。